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Dear Dr. Nahum Méndez-Sánchez 
Editor in chief of Annals of Hepatology 
---------------------------------------- 
Ref. ANNHEPATOL-D-14-00147 
 
We are submitting a revised version of our manuscript “"Inter and intrapatient 
evolution of Hepatitis C virus" by Di Lello et al.” We have considered all the reviewer's 
observations. We hope that now the revised manuscript will be suitable for publication. 
Thanking you in advance for your kind attention and support, we remain 
respectfully yours.   
 
 
Dr. Federico A. Di Lello 
 
  
Cover Letter
Response to the reviewers: 
First, we would like to thank your pertinent and helpful comments and suggestions to 
improve our study.  
Our responses appear in bold below your comment. 
 
Reviewer #1: ANNHEPATOL-D-14-00147 
This is an interesting review where authors address the evolution within and among 
patients of hepatitis C virus (HCV). This manuscript could help to better understand the 
natural history of the virus and its potential implications in epidemiology, outcome of 
infection and the progression of liver disease.  
 
Major comments: 
1. In Paragraph: "The evolution of HCV is mostly determined by its own? Extremely 
complex to study" authors should add references at the end of these facts.  
Author´s reply: The references were added in the revised manuscript at the end 
of each statement (Page 3). 
 
2. Page 6: references 24-26 do not correspond to the statements in this paragraph. 
More appropriate references should be added to the text described. 
Author´s reply: As you suggested, the paragraph was modified and more 
appropriate references were added to the text described in the revised 
manuscript (page 5).  
 
3. Page 8, in paragraph. "Additionally, HCV diversity has also implications for the 
transmission. At the 1980-90s it was known? "Authors should add references at the 
end of these facts. 
Author´s reply: The references at the end of these facts were added in the 
revised manuscript and the phrase “At the 1980-90s…” was removed (page 6) 
 
4. Authors should carefully review the manuscript to complete all necessary references 
in the appropriate place in the manuscript, ej. Page 10, first paragraph, there are not 
references in these facts, authors should add it. 
Author´s reply: The manuscript was carefully review and the citation was added 
in the revised manuscript (page 9) 
 
5. It would be interesting to discuss the meaning and impact of these concepts of viral 
genetic variability and its relation to clinical presentation and outcome of patients 
infected with HCV, in order to understand how genetic variability affects pathobiology of 
the disease.  
Author´s reply: According to the reviewer’s comment, a discussion about this 
topic has been added to the text in the section “Intrapatient Evolution” (page 8 
and 9). 
 
6. It would be interesting to describe the intrapatient genetic variability in presence and 
absence of antiviral treatment in those with SVR and non-response. 
Author´s reply: This topic was described and the references were added 
accordingly in the section “Intrapatient Evolution” (page 9). 
 
7. It could be helpful for readers to add as a fig 1, a schematic picture about bottleneck 
effect over genetic variability and predominance of viral clusters and further intra and 
inter-patients virus evolution. 
Author´s reply: We consider that the phylogenetic trees presented in the original 
manuscript already show by itself the bottlenecks effect in the genetic diversity. 
However, we amended the figures to highlight those events. In this way, a 
schematic picture about bottleneck effect (indicated with arrows or dotted lines) 
over genetic variability and predominance of viral clusters and further intra and 
inter-patients virus evolution was added as a part of figures 1 and 2. Additionally, 
the genetic diversity trough the time measured by the Bayesian Skyline 
methodology was added as a light blue shaded area in each figure.  
 
8. Figure 1 and 2, in order to get readers attention, graphics should be more 
informative. Same for both.  
Author´s reply: Changes have been applied accordingly. 
 
  
Reviewer #2: Summary: in this review the authors discuss inter and intrapatient 
evolution of hepatitis C, with development of quasispecies. 
Comments: 
 
1. The authors suggest that intrapatient evolution of quasispecies is important for the 
success or failure of antiviral therapy. Could they further support this proposal with 
evidence? Are specific quasispecies identified during unsuccessful antiviral therapy 
compared to basal? 
Author´s reply: The text was modified accordingly and the effect of quasispecies 
evolution on HCV treatment was discussed and referenced (see Intrapatient 
Evolution section: page 9). 
 
2. The authors state that: "For this reason, the initial enthusiasm and confidence in the 
combinations based on the direct-acting antiviral (DAA) therapy have been tempered 
by the evidence of the rapid emergence of resistant variants to DAA during these 
treatments (49-51)."In the opinion of the reviewer this is a remarkable statement in 
2014, with the introduction of various DAA and sustained viral response rates of more 
than 90%. 
Author´s reply: According to review suggestions the phrase in the original 
manuscript was replaced by: …“Thus, a rapid emergence of resistant variants 
was detected in the majority of patients with treatment failure to direct-acting 
antiviral (DAA)…”, (Page 7). 
 
3. The authors are mainly focused on viral evolution. I would advise to add a discussion 
with some detailed information on the current concepts of innate and adaptive host 
immunity in relation to hepatitis C virus (clearance vs persistence).  
Author´s reply: As you suggested, a brief discussion with the current concepts 
of innate and adaptive host immunity in relation to hepatitis C virus was added in 
the first paragraph of page 7. 
 
4. Of note it has been reported that hepatitis C virus infection at young age is 
associated with better spontaneous clearance than infection at later age (e.g. studies in 
hemophiliac’s bj Mauser-Bunschoten et al. Could the authors comment on this in 
relation to quasispecies evolution? 
Author´s reply: The topic about the impact of host age in the quasispecies 
evolution of HCV is very interesting and may be a useful piece of information in 
the pediatric field. Additionally to the report that you pointed out (which was 
included in the revised manuscript, page 7 and reference number 47), other 
reports may show that viral diversity is associated with different outcomes in 
adult and children patients (Gismondi MI, et al. J Viral Hepat 2009;16:332-9, Valva 
P, et al. 2014 Jun 19. doi: 10.1111/1469-0691.12728. [Epub ahead of print]). 
However, we preferred not to discuss in detail this topic because of the overall 
length of the review. 
 
5. The review could be shortened a bit. 
Author´s reply: because both reviewers asked for additional information we 
could not shorten the review. However, we removed some sections of the review 
in order not to extend it even more.  
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Manuscript
ABSTRACT  
Hepatitis C virus (HCV) has a short replication time, high mutation rates and large 
population sizes, all of which make it an excellent experimental model for evolution 
studies, because evolution can be visualized in real-time. In this review, we discuss the 
implications to study HCV evolution at the interpatient and intrapatient levels of 
infection. The HCV interpatient dynamics is relatively slow, because the generation 
time is generally long. Then, at population level, the HCV diversity originated by the 
high mutation and replication rates is modulated by the bottleneck at transmission. 
Thus, when the virus is transmitted to other hosts, viral diversity is reduced as a result 
of the founder effect. On the other hand, during intrapatient infection, HCV evolves 
rapidly, resulting in quasispecies. Accumulated evidence suggests that this 
quasispecies composition of the HCV population within the same individual may allow 
the virus to evade the immune response or escape treatment, leading to chronic 
infection. Thus, a better understanding of the complexities underlying the molecular 
evolution of HCV in natural populations is needed before accurate predictions of viral 
evolution can be made. In summary, HCV evolves both within and among patients. 
Consequently, HCV evolution should be studied at both levels in order to better 
understand the natural history of the virus and its potential implications in 
epidemiology, outcome of infection and progression of liver disease.  
 
KEYWORDS: HCV; quasispecies; liver disease. 
  
INTRODUCTION 
Hepatitis C Virus (HCV) is an enveloped single-stranded positive RNA virus (1) that 
currently infects approximately 3% of the world’s population (2). In about 80% of 
infections, HCV causes a silent chronic hepatic illness that can lead to fibrosis, 
cirrhosis and hepatocellular carcinoma (3). This RNA virus displays high genetic 
diversity. Seven genetic clades and various subtypes have been described and are 
associated either with a specific geographic distribution or with different biological 
features (4-8). HCV evolves very rapidly during the progress of infection, resulting in 
genetically diverse viral populations whose composition is determined by a combination 
of evolutionary processes that include a short generation time, high mutation rates, 
large population sizes, natural selection and random genetic drift. All these 
mechanisms allow adaptation of viruses to selective pressures and make HCV an 
excellent experimental model where evolution can be monitored in real-time (9,10). The 
evolution of HCV is mostly determined by its own characteristics and by host-mediated 
or antiviral selection pressures (11-17). Nevertheless, despite their apparent simplicity 
and advantages, viral populations exhibit features that make their evolutionary 
dynamics extremely complex to evaluate (11,12). Firstly, in nature, HCV exists in an 
intricate hierarchy of populations, from single infected cells to global pandemics. 
Secondly, the long infectious periods, which are in the order of years, mean that both 
inter- and intrapatient evolutionary patterns can be observed. Additionally, HCV also 
exists within its hosts as a dynamic pool of genetically distinct but closely related 
variants referred to as ‘‘quasispecies’’ (11,12). Accordingly, HCV appears to exhibit 
qualitatively different evolutionary dynamics when its genetic diversity is studied at 
different levels. In this way, the substitution rate of HCV may differ in intra- and 
interpatient as well as among the different regions of the genome. Then, its fast 
adaptation allows this virus to prevail over natural or artificial barriers such as host 
defenses, pathogeny and drug therapy (13-17).  
As mentioned above, regardless of their rapid growth, HCV virus populations suffer 
repeated bottlenecks, both within hosts and when transmitted from host to host. The 
population bottleneck can be defined as a marked reduction in the number of viral 
genomes within a population which leads to significant effects. Particularly, intrapatient 
evolutionary effects of bottlenecks can be observed by comparing sequences of 
quasispecies that represent different virions from a single chronically infected patient 
over several years (18,19). On the other hand, in interpatient evolution, the size of the 
viral population replicating is a very informative point to consider. Additionally, when the 
virus is transmitted, selection can act deeply in large populations, whereas the random 
effect of genetic drift is more severe in small populations.  
Thus, one of the largest distinctions between these two levels is that interpatient 
evolution is mostly conducted by numerous bottlenecks arising from transmission 
events, whereas in intrapatient evolution the bottlenecks are not very relevant while the 
patient is not treated (20). The two patterns outlined above suggest that different 
evolutionary and population genetic processes should be inferred from inter- and 
intrapatient sequence data. For all these reasons, understanding HCV evolution is 
important itself but also in view of the fact that viral diversity could be relevant in the 
outcome of the infection and liver disease progression (7, 8, 21-23). 
  
INTERPATIENT EVOLUTION 
As it happened with HIV, HCV may have been transmitted to humans through 
interspecific infections that were only possible with the demographic changes that 
occurred 50-100 years ago. The fact that HCV is transmitted mainly through parenteral 
routes implicates the transmission through unsterilized needles, blood transfusion and 
injecting drug use (IDU). The current HCV screening and the expansion of needle 
exchange programs have led to reductions in blood transfusion risk and significant falls 
in HCV incidence among IDUs (24). For this reason, the HCV interpatient dynamics is 
relatively slow, since the time between transmission events is generally long (months 
or years) (25). Then, at population level, the HCV diversity originated with high viral 
mutation and replication rates is modulated by the bottleneck at transmission (26). 
Each new host represents a novel environment for the virus. Such extreme genetic 
bottleneck associated with transmission may largely depend on the structure of the 
virus population in the donor host, the virus genotype, the host factors, and the rapid 
and radical decline in population size that normally reduces the population's genetic 
diversity. Accordingly, bottleneck could be enhanced by the influence of host factors 
such as the favorable IL28B genotype rs12979860 (CC) that was associated with the 
spontaneous clearance (SC) of HCV in several studies (27, 28). Additionally, the HCV 
non-1 genotypes have also been related with SC increasing the importance of HCV 
diversity in the persistence and pathogeny of this virus (29).  
 
On the other hand, if the structure of virus population is genetically heterogeneous, 
transmission bottlenecks could be determined partially by the genetic diversity 
available in the host. Therefore, among-virus competition after transmission typically 
generates a strong population bottleneck, making it very unlikely that multiple viral 
lineages will be repeatedly transmitted (30-32). Consequently, the phylogenetic 
structure of HCV at the population level reflects the demographic and spatial history of 
transmission (26). In this context, it is known that HCV phylogenetic trees often span 
several decades so the time when two viral lineages coalesce is close (relative to the 
timescale of the phylogeny) to the actual transmission times. Accordingly, interpatient 
phylogenies of HCV sampled through time are not stepwise and show the persistence 
of multiple lineages through time (Figure 1). The shapes of these trees are primarily 
determined by neutral demographic and spatial dynamics in both immune-mediated 
positive selection and purifying selection for replication ability (26-33). In this way, the 
evolutionary analysis has shed light on the origins of HCV and on the epidemic spread 
of viral variants in different geographic locations and populations.  
Additionally, HCV diversity has also implications for the transmission. It is known that 
genotype distribution is associated with the mode of transmission, with subtypes 1a, 3a 
and 4 being mostly IDU-related and genotypes 1b and 2 associated with blood 
transfusion and unsafe medical procedures (34-36). Currently, this distribution is 
changing due to the controls in transfusion procedures, the increment of IDUs, the 
immigration and the controls in vertical and sexual transmission. A clear example of 
this is the increasing prevalence of genotype 4 in Europe (36-39). HCV genotype 4 is 
considered a difficult-to-treat genotype in HCV-monoinfected and HIV/HCV coinfected 
patients, because the rate of sustained virological response to pegylated interferon plus 
ribavirin is poorer than that for HCV genotypes 2 or 3 (8, 40-43). Then, this issue is of 
importance since the HCV genotype and subtype are also very relevant in terms of 
antiviral therapy.  
INTRAPATIENT EVOLUTION 
HCV is among the most successful of all persistent human viruses. Chronic infection is 
seen in up to 75% of those infected by successfully undermining virus-specific 
immunity (44). Previous studies suggest that HCV alters the host defense and innate 
immunity early during infection through a variety of complementary mechanisms, 
thereby facilitating chronic infection and leaving host defenses to other infectious 
agents intact (45). The mechanism responsible for the high rate of persistence is 
attributed to the efficient capacity of generation and fixation of escape mutants 
associated to HLA in the non structural protein of HCV, which allows the virus to evade 
the adaptive and innate components of the host’s immune system (46). Additionally, 
HCV capacity of persistence is strongly influenced by the age and the nature of the 
host’s innate and adaptive antiviral immunity. In this sense, several studies had shown 
that IL28B, CXCL10, IFNL3, HLA class I and II are associated with outcome of HCV 
and may explain an important percentage of spontaneous clearance of HCV infection 
(47-53). The misincorporation of nucleotides during HCV replication and the 
subsequent effects of selection pressure, from either neutralizing antibodies or 
cytotoxic T lymphocytes, as well as the drift that fix substitutions in populations, 
represent the fundamental driving force in intrapatient evolution (21, 54, 55). As a 
consequence, HCV evolves very rapidly during intrapatient infection, resulting in 
variants whose dynamic composition is determined by a combination of evolutionary 
processes that include mutation, replication rate, natural selection, and random genetic 
drift at transmission time. In this sense, accumulated evidence suggests that the 
genetic variation of HCV within the same individual may allow the virus to evade the 
immune response, leading to chronic infection (19). Virtually in a patient infected with 
HCV, it is likely that all possible variants are present in the quasispecies at every 
moment. However, the point is to determine which the threshold of variant frequency 
for establishing a particular phenotype is, either a variant resistant to treatment or a 
variant causing more severe liver damage. Thus, a rapid emergence of resistant 
variants was detected in the majority of patients with treatment failure to direct-acting 
antiviral (DAA) (56-59). However, this is not an unexpected finding. Naturally, HCV can 
produce approximately 1012 virus particles per day (60). Furthermore, the viral 
replication complex lacks proofreading capacity, leading to a large number of mutants. 
As a result, the virus population is a highly complex and continuously changing mutant 
spectrum or mutant cloud known as quasispecies (61). These are the lowest level of 
viral heterogeneity variation with only 1 to 2% and, thus, the major challenge with 
regard to resistance to treatment (61). Despite the fact that, in theory, an active HCV 
infection can produce all possible mutants in just one day, not all are able to persist in 
the population. This is because, in the viral genome, there are constraints with 
restrictions to change since most mutations generate viral variants that have a reduced 
replicative ability and, therefore, do not proliferate. However, this will surely be different 
for each patient because of the multiplicity of factors involved in each process related 
to viral infection. 
 
Phylogenetic analyses of intrapatient evolution reconstructed from HCV genomes 
sampled from multiple time points have mostly revealed two or more genetically distinct 
co-existing viral lineages that are not detected at all sampling times (Figure 2). This 
phenomenon is seen in both acute (62) and chronic infection (17, 63-65). Then, the 
intrapatient tree topology is manifested by a temporal structure that shows continual 
adaptation to the patient immune responses and by high rates of lineage extinction 
which result in a modest genetic diversity at any time point. This suggests that the 
succeeding viral population is not always immediately derived from the preceding 
population and sometimes would be the effect of evolutionary shift. Briefly, regardless 
of the complexity or diversity of the viral populations at the early stage of infection, HCV 
evolves towards genetic diversification following selective pressure. Once the 
environment becomes stable, the entire population tends towards homogeneity (18). 
Then, HCV intrapatient evolution, which may be driven by adaptive selection, becomes 
important from a clinical perspective because it contributes to the variability in disease 
progression and development of drug resistance. In this sense, pathobiological studies 
linking nucleotide and amino acid sequences with clinical findings have identified 
relationships between certain genotypes and characteristic biological properties (23). 
For example, HCV-3 infection was found to be associated with a high level of liver 
steatosis (66). At quasispecies level it has been reported that an increase in HVR1 
diversity during acute infection predicts progression to chronic disease, whereas a 
decrease correlates with resolution of the disease (21). 
On the other hand, it has been extensively described the effect of genetic variability 
between HCV genotypes and subtypes on response to therapy. HCV-1 and 4 were 
found to be more resistant to interferon based therapies than HCV-2 and 3 and, in the 
same way, HCV-1b respond better than HCV-1a (67,68). However, there is 
contradictory data about the influence of quasispecies on treatment response (69-72). 
Some reports have demonstrated that resistant mutants are present in DAA naïve-
patients as either dominant or minority species (56, 73). When treated with DAA, 
resistant variants, initially present as minority species, may expand to occupy the free 
replicative space, thus becoming the dominant variant (72, 74). Consequently, this may 
lead to failure of antiviral regimen. In this context, it has been reported that mutations 
need to be present at a certain frequency to result in a measurable phenotypic effect 
(75, 76). However, more recently, literature has emerged that offers contradictory 
findings about this topic (72, 77). For all these reasons, the study of viral genetic 
variation and the emergence of drug resistance are of major importance in the era of 
new treatments. 
 
CONCLUSION 
In intrapatient evolution, once the virus is installed in the new host, the first molecular 
events occurring immediately after may result in the generation of a highly 
heterogeneous viral population (20,26). Subsequently, the HCV specific adaptive 
immunity probably shapes this founder population into a dynamic quasispecies 
complex, each of which may become dominant at different phases of HCV infection. 
Then, negative selection acts to achieve a stable adaptation to the host. HCV evolution 
is therefore defined mainly by two distinct mechanisms: drift and shift on the variants 
present in a chronic infected patient. This consideration implies that succeeding 
dominant subpopulations may not be directly derived from each other but may rather 
share a common ancestor.  
Lastly, in the interpatient evolution, the transmission to a new host represents a novel 
environment for the virus. Such extreme genetic bottleneck may largely depend on the 
inoculum and the structure of the virus population in the donor host.  
In conclusion, the long infectious period of HCV means that evolution occurs both 
within and among patients. Consequently, the evolution of HCV should be studied both 
at interpatient level (bottleneck at transmission) to better understand the natural history 
of the virus and its potential implications in epidemiology and, at intrapatient level 
(adaptation to the exogenous and host´s pressures) to better understand the outcome 
of infection and the progression of liver disease.  
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FIGURE LEGENDS 
 
Figure 1 
Interpatient evolution of HCV in a country. Maximum Clade Credibility Tree constructed 
by Bayesian coalescent methodology from direct sequences of the first half of the E2 
region in plasma samples from HCV genotype 1a isolations in Argentina. The tree is 
presented in time scale (calendar years). The overall process is depicted by the 
diversification of the current lineages from the 60's to the 80's independently of the 
actual time of sampling. The arrows indicate possible bottleneck effects. The dark red 
one indicates the possible introduction of HCV in the community, whereas the magenta 
ones may indicate the acquisition of the virus by different routes of transmission. 
Virtually, every transmission event is thought to be a bottleneck effect for virus 
diversity. The light blue shaded area represents the viral genetic diversity trough the 
time measured by the Bayesian Skyline methodology [65]. 
Figure 2 
Intrapatient evolution of HCV in an 8-year follow up. Maximum Clade Credibility Tree 
constructed by Bayesian coalescent methodology from cloned sequences of the first 
half of the E2 region in serially obtained plasma samples from a single patient. The tree 
is presented in time scale (years before present). Each symbol (star, circle, diamond, 
hexagon, triangle and square) represents different viral lineages. The colors indicate, 
as the axis position does, the time of the sampling. The vertical dark red dotted lines 
represent bottleneck events where one of the lineages (shapes) got extinct. The overall 
process is depicted by the modification or extinction of existing lineages (quasispecies 
shift). The light blue shaded area represents the viral genetic diversity trough the time 
measured by the Bayesian Skyline methodology [65].  
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